Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gerwin G. W. Sandker"'
Autor:
Jim Middelburg, Marjolein Sluijter, Gaby Schaap, Büşra Göynük, Katy Lloyd, Vitalijs Ovcinnikovs, Gijs G. Zom, Renoud J. Marijnissen, Christianne Groeneveldt, Lisa Griffioen, Gerwin G. W. Sandker, Sandra Heskamp, Sjoerd H. van der Burg, Tsolere Arakelian, Ferry Ossendorp, Ramon Arens, Janine Schuurman, Kristel Kemper, Thorbald van Hall
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory hematological malignancies, but responses in solid tumors have been limited so far. One of the main hurdles in solid tumors is the lack of sufficient T-cell inf
Externí odkaz:
https://doaj.org/article/36795cab2cda485e96053669065dc63a
Autor:
Gerwin G. W. Sandker, Gosse Adema, Janneke Molkenboer-Kuenen, Peter Wierstra, Johan Bussink, Sandra Heskamp, Erik H. J. G. Aarntzen
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundProgrammed death-ligand 1 (PD-L1) regulates immune homeostasis by promoting T-cell exhaustion. It is involved in chronic infections and tumor progression. Nuclear imaging using radiolabeled anti-PD-L1 antibodies can monitor PD-L1 tissue exp
Externí odkaz:
https://doaj.org/article/785887c64a7e45628531f9d9e709f550
Autor:
Massis, Krekorian, Gerwin G W, Sandker, Kimberley R G, Cortenbach, Oya, Tagit, N Koen, van Riessen, René, Raavé, Mangala, Srinivas, Carl G, Figdor, Sandra, Heskamp, Erik H J G, Aarntzen
Publikováno v:
Bioconjugate Chemistry
With the advent of novel immunotherapies, interest in ex vivo autologous cell labeling for in vivo cell tracking has revived. However, current clinically available labeling strategies have several drawbacks, such as release of radiolabel over time an